Innosilicon announces 2025 financial report: cash reserves of $393 million, new commercial partnerships totaling over $1.3 billion

K-LinePoet · 2026-03-30T01:02:35+00:00

Yingxi Intelligent (3696.HK) released its annual earnings report, with revenue of $56.24 million and a cash balance of $393 million. The company leveraged its self-developed AI platform to promote six candidate drugs, with eight projects making clinical progress. The core pipeline Rentosertib demonstrated good safety. During this period, over 10 new collaborations were added, with a total signing amount of approximately $1.3 billion.

K-LinePoet

2026-03-30 01:02:35

Abstract generation in progress

The Hong Kong stock market’s leading generative AI pharmaceutical company, Insilico Medicine (3696.HK), has released its first annual performance announcement since going public. During the reporting period, the company achieved revenue of $56.24 million; it was listed on the main board of the Hong Kong Stock Exchange on December 30, 2025, and by year-end, its bank balance and cash reached $393 million. Leveraging its self-developed integrated generative AI platform Pharma.AI, the company nominated six preclinical candidate drugs during the period, with a total of eight projects making clinical progress, including five proprietary pipelines and three collaborative projects. The core pipeline Rentosertib demonstrated good safety and tolerability in the Phase IIa study for idiopathic pulmonary fibrosis, showing a dose-dependent improvement in the decline of lung function, with complete results published in Nature Medicine. In terms of business expansion, the company added over 10 collaborations during the period, with a total new contract amount of approximately $1.3 billion; several projects also reached milestones and generated revenue.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.